KRISHGEN BIOSYSTEMS expands ELISA kits product range with acquisition of KinesisDx, USA Products

Mumbai, Jul 11, 2019 ( – KRISHGEN, today announced that, as on July 11, 2019, it entered into a License and Commercialization Agreement with life sciences and reagents manufacturer, KinesisDx, USA, which provides Krishgen with worldwide distribution, development and commercialization rights to KinesisDx’s product line for use in research life sciences and clinical markets for undisclosed amount.

Krishgen will be the exclusive worldwide distributor of KinesisDx’s product ranges for use in life sciences and clinical market. Krishgen will be the sole and exclusive user of KinesisDx brand and logo.

More on StockNewDesk:

“Krishgen is uniquely positioned to provide life sciences products to clinicians, researchers, CROs and pharmaceutical companies worldwide. We continue to deliver on our promise to bring the best technologies and products at affordable prices. 


Krishgen Biosystems, headquartered in Mumbai, India is a bio-supplier focused on offering solutions for immunoassays, cell cultures, and toxicology to researchers. Krishgen offers products across the research and drug discovery segment including GENBULK, GENLISA, KRISHZYME, KRISHGEN, KRIBIOLISA, KRISHPLEX, TITANIUM.

For more information, please visit:

More on StockNewDesk:

Forward Looking Statements
This press release contains forward-looking statements about our business, research, development and commercialization efforts, including statements regarding the development and commercialization of future products and our ability to bring solutions to the research and biopharmaceutical segment. These forward-looking statements are based upon information that is currently available to us and our current expectations, speak only as of the date hereof and are subject to numerous risks and uncertainties, including risks associated with successful research, development and planned commercialization of our technologies. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.

Kalpesh Jain
Chief Operating Officer
[email protected]

Media Contact


[email protected]


Unit Nos 318 319 Shah and NaharOff Dr E Moses RoadWorli


This article was originally published by IssueWire. Read the original article here.

Latest on StockNewDesk:


Lost your password?